Secnidazole

Secnidazole
Clinical data
Trade names	Solosec
Other names	PM 185184, RP 14539
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	P01AB07 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name 1-(2-Methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol;
CAS Number	3366-95-8 ;
PubChem CID	71815;
ChemSpider	64839 ;
UNII	R3459K699K;
KEGG	D07353 ;
ChEMBL	ChEMBL498847 ;
CompTox Dashboard (EPA)	DTXSID3045934 ;
ECHA InfoCard	100.020.123
Chemical and physical data
Formula	C7H11N3O3
Molar mass	185.180 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-][N+](=O)c1cnc(n1CC(O)C)C;
	InChI InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3 ; Key:KPQZUUQMTUIKBP-UHFFFAOYSA-N ;
(what is this?) (verify)

Secnidazole (trade names Flagentyl, Sindose, Secnil, Solosec) is a nitroimidazole anti-infective. Effectiveness in the treatment of dientamoebiasis has been reported.[1] It has also been tested against Atopobium vaginae.[2]

In the United States, secnidazole is approved for the treatment of bacterial vaginosis in adult women.[3]

References

Girginkardeşler, N.; Coşkun, S.; Cüneyt Balcioğlu, I.; Ertan, P.; Ok, U. Z. (2003). "Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole". Clinical Microbiology and Infection. 9 (2): 110–113. doi:10.1046/j.1469-0691.2003.00504.x. PMID 12588330.
De Backer, E.; Dubreuil, L.; Brauman, M.; Acar, J.; Vaneechoutte, M. (2009). "In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis". Clinical Microbiology and Infection. 16 (5): 470–472. doi:10.1111/j.1469-0691.2009.02852.x. PMID 19548924.
"FDA Approves Symbiomix Therapeutics' Solosec (secnidazole) Oral Granules for the Treatment of Bacterial Vaginosis in Adult Women" (Press release). Symbiomix Therapeutics.

External links

Gillis, J. C.; Wiseman, L. R. (1996). "Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis". Drugs. 51 (4): 621–38. doi:10.2165/00003495-199651040-00007. PMID 8706597.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Girginkardeşler, N.; Coşkun, S.; Cüneyt Balcioğlu, I.; Ertan, P.; Ok, U. Z. (2003). "Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole". Clinical Microbiology and Infection. 9 (2): 110–113. doi:10.1046/j.1469-0691.2003.00504.x. PMID 12588330.

[2] De Backer, E.; Dubreuil, L.; Brauman, M.; Acar, J.; Vaneechoutte, M. (2009). "In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis". Clinical Microbiology and Infection. 16 (5): 470–472. doi:10.1111/j.1469-0691.2009.02852.x. PMID 19548924.

[3] "FDA Approves Symbiomix Therapeutics' Solosec (secnidazole) Oral Granules for the Treatment of Bacterial Vaginosis in Adult Women" (Press release). Symbiomix Therapeutics.